Immunocore Holdings plc announced that Dr. David Berman, Executive Vice President of Research and Development, will leave the company effective February 27, 2026. The company will not appoint a direct replacement and will instead streamline its R&D organization around the existing leadership team.
In the same announcement, Immunocore promoted Chief Medical Officer Dr. Mohammed Dar and Head of Regulatory Sciences Mark Moyer to Executive Vice President positions. The new EVP roles give Dar and Moyer expanded oversight of clinical development and regulatory strategy across the company’s oncology, infectious‑disease, and autoimmune portfolios.
Dr. Berman’s departure follows his leadership of the Phase 3 trial that secured FDA approval for KIMMTRAK (tebentafusp‑tebn) in January 2022. KIMMTRAK has become a key revenue driver, generating $93.9 million in Q1 2025— a 33 % year‑over‑year increase—and is approved in 39 countries. The company’s pipeline includes three ongoing Phase 3 studies, and Berman’s experience is seen as foundational to that progress.
The restructuring reflects Immunocore’s strategy to accelerate clinical programs and regulatory approvals while maintaining a lean R&D footprint. CEO Bahija Jallal said, “David has been instrumental in delivering the Phase 3 trial that led to the approval of KIMMTRAK and in positioning our rich pipeline for success, including three ongoing Phase 3 trials.” By elevating Dar and Moyer, Immunocore signals confidence that the expanded leadership will sustain momentum in development and regulatory execution.
Financially, Immunocore is well‑capitalized, with a market value of approximately $1.67 billion and more cash than debt. As of January 30, 2026, the company had $837 million in cash, cash equivalents, and marketable securities. The upcoming Q4 2025 earnings are expected on February 25, 2026, with a conference call scheduled for February 26, 2026.
The leadership changes are expected to have limited short‑term impact on financial guidance but underscore Immunocore’s commitment to a distributed leadership model that can adapt quickly to the demands of its global pipeline. No immediate market reaction data is available, but the announcement is likely to be viewed as a positive step toward sustaining the company’s growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.